Extends leadership in digital health innovation and launches pilot
initiative around first ever FDA cleared prescription digital
therapeutic from PEAR Therapeutics
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--
Health, Inc. (NASDAQ: MGLN) has long been the national leader in the
use of digital innovation to help those struggling with various medical
and behavioral conditions, including Substance Use Disorders (SUD). As a
pioneer in the use of digital therapeutics and computerized cognitive
behavioral therapy (CCBT), Magellan has engaged in a new initiative
designed to measure clinical outcomes in patients with SUD by leveraging
reSET®, the first ever FDA cleared prescription digital
therapeutic from PEAR Therapeutics.
The pilot program will enroll 250 patients with SUD and offer each
patient a 12-week course of reSET® therapy. The collaboration
aims to examine patient abstinence and program retention through
increased engagement and therapy adherence. The pilot will use advanced
data analytics generated through the reSET® therapy and
accompanying clinician dashboards to more effectively provide technical
support and clinical outreach to both treatment providers and their
patients. Magellan will also work with PEAR to develop a series of
publications highlighting the operational, economic and clinical results
of this pilot program.
Magellan believes this pilot will help support the broader strategy to
engage consumers in ways that match the best of new and traditional
methods to drive optimal outcomes. This pilot will be important to help
understand the value such FDA approved solutions bring to the healthcare
market, as well as the operational requirements needed to support
digital therapeutics in the future.
"As a national leader in providing behavioral health and pharmacy
services, Magellan is committed to bringing innovative, member-centric
programs to the marketplace," said Maria Lopes, M.D., chief medical
officer at Magellan Rx Management. "This prescription digital
therapeutic alternative offers physicians and members an evidence-based,
non-drug treatment option, which is critical when you consider our
nation's current challenges with substance use. Industry collaborations
like this allow us to rethink the way treatment is delivered and offer
practical solutions to meet the complex needs we face today."
According to the Substance Abuse and Mental Health Services
Administration (SAMHSA), approximately 20.2 million adults have a type
of SUD in the United States. Cognitive behavioral therapy, such as reSET®,
is widely recognized as an important component of an overall treatment
regimen for SUD. reSET® is a 12-week duration, FDA-cleared
prescription digital therapeutic to be used in conjunction with standard
outpatient treatment for substance use disorder related to stimulants,
cannabis, cocaine, and alcohol.
This product combines patient-facing interventions and assessments via a
mobile device, with clinician-facing dashboards and data analytics on
the back-end. reSET® has been shown in clinical studies to
increase abstinence from a patient's substances of abuse during
treatment and increase patient retention in the outpatient treatment
program. reSET® provides access to self-reported substance
use, triggers, cravings and outcomes to the patient's medical provider.
"This is an important collaboration for PEAR as we seek to bring reSET
to patients with SUD," said Corey McCann, M.D., Ph.D., president and
chief executive officer of PEAR Therapeutics. "We believe that
prescription digital therapeutics hold great promise in improving
patient outcomes across a wide range of central nervous system disorders
including psychiatry, neurology and pain, and will become a vital part
of tomorrow's treatment paradigm across all disease areas. Collaborating
with a company like Magellan will help PEAR get this innovative solution
to patients who need it most."
About Magellan Health: Magellan
Health, Inc. is a leader in managing the fastest growing, most
complex areas of health, including special populations, complete
pharmacy benefits and other specialty areas of healthcare. Magellan
supports innovative ways of accessing better health through technology,
while remaining focused on the critical personal relationships that are
necessary to achieve a healthy, vibrant life. Magellan's customers
include health plans and other managed care organizations, employers,
labor unions, various military and governmental agencies and third-party
administrators. For more information, visit MagellanHealth.com.
About PEAR Therapeutics: PEAR Therapeutics is the leader in
FDA-cleared prescription digital therapeutics. The company's approach is
to integrate clinically-validated software applications with previously
approved pharmaceuticals and treatment paradigms to provide better
outcomes for patients, smarter engagement and tracking tools for
clinicians, and cost-effective solutions for payers. PEAR's lead
product, reSET®, is an FDA-cleared 12-week prescription
therapeutic for the treatment of Substance Use Disorder (SUD) to be used
as an adjunct to standard, outpatient treatment. PEAR's product
development pipeline includes reSET-O™ for opioid use disorder (OUD) and
additional prescription digital therapeutics in schizophrenia (THRIVE™),
combat posttraumatic stress disorder (reCALL™), general anxiety disorder
(reVIVE™), pain, major depressive disorder, and insomnia, for which PEAR
intends to obtain FDA clearance. For more details, please see www.peartherapeutics.com.
About Prescription Digital Therapeutics: Prescription digital
therapeutics are clinically validated, FDA-cleared software applications
that demonstrate safety and efficacy in randomized clinical trials to
improve patient outcomes. They usually include patient-facing
applications, clinical assessment and outcomes tracking, clinician
monitoring dashboards and HIPAA-compliant data storage.
reSET® Indications for Use: reSET®
is intended to provide cognitive behavioral therapy, as an adjunct to a
contingency management system, for patients 18 years of age and older
who are currently enrolled in outpatient treatment under the supervision
of a clinician. reSET® is indicated as a 12-week
prescription-only treatment for patients with substance use disorder
(SUD), who are not currently on opioid replacement therapy, who do not
abuse alcohol solely, or who do not abuse opioids as their primary
substance of abuse. Full prescribing information can be found at www.peartherapeutics.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180116006754/en/
Magellan Health, Inc.
Joe Bogdan, 860-507-1910
Source: Magellan Health, Inc.
News Provided by Acquire Media